Universal Corporation

Thank you for standing by. My name is Gail, and I will be your conference operator today. At this time, I would like to welcome everyone to the Universal Corporation's fourth quarter fiscal year 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, simply press star one again. I would now like to turn the conference over to Wushma. Vice President and Treasurer, you may begin.

Good morning, and thank you for joining us. With me today are President Wigner, our Chairman, President, and CEO, and Steve Deal, our recently appointed Chief Financial Officer. During the course of this call, we will be making forward-looking statements that are based on our current knowledge and some assumptions about the future. These are representative as of today only. Actual results, performance, or achievements could differ materially from the anticipated results, prospects, performance, or achievements expressed or implied by such forward-looking statements. And we assume no obligation to update any forward-looking statements except as required by law. For information on some of the risks and uncertainties related to these forward-looking statements, please refer to the reports we filed with the ICC and under cautionary statement regarding forward-looking statements in our current earnings price release. Finally, some of the information we have filled today may be based on unaudited allocations and may be subject to reclassification. Our comments today may also include certain non-GAAP financial measures. For details regarding these measures, including the reconciliation of these non-GAAP measures to the most comparable GAAP measures, Please refer to our current earnings price release and other public materials. This call is being webcast live and will be available for replay on our website through August 29, 2026, and by telephone through June 12, 2026. This call is copyrighted and may not be used without our permission. Other than the reference replay, we have now authorized and disclaimed responsibility for any recording, replay, or distribution of any transcription on this call. I would like now to turn the call over to Preston.

Thank you, Woosh. Good morning, everyone, and thank you for joining us today. Our fiscal year 2026 performance reflected solid execution across much of our business. operating in a market environment that shifted meaningfully from the prior year. We saw oversupply in certain tobacco styles and continued market headwinds in our ingredients business, which impacted volumes and margins. Amidst these challenges, our teams around the globe demonstrated the resilience of our tobacco operations, and we continue to focus on the progress we are making to support the long-term growth of our ingredients operations. However, Our financial results for the fourth quarter and fiscal year were impacted by a non-cash goodwill impairment related to our universal ingredient shanks operation and by inventory write-downs primarily related to non-wrapper dark air cured tobacco. We remain confident in our tobacco and ingredient strategies and the steps we've taken to adapt to current market conditions and position the business for the future. With more than 100 years of operating experience and a market-leading position, our leaf tobacco business has demonstrated its durability across market cycles. At the same time, we believe our ingredients strategy, which focuses on innovation and solution-based products, is well aligned with customer needs and long-term value creation. We have invested over several years to build a scalable ingredients platform with necessary capacity and capabilities, and we believe the platform is well positioned for future growth. Supporting both these priorities is our continued advancements in sustainability, which remains an increasingly important expectation across our global value chain. During the fourth fiscal quarter, Universal advanced from an A- to an A rating in the Carbon Disclosure Project's Supplier Engagement Assessment. In addition, we were recognized as a CDP Supplier Engagement Leader and named to CDP's Supplier Engagement A-List, underscoring the strengths of our governance, admissions management, and collaboration with suppliers. Strong financial discipline and leadership are critical to executing across both our operating segments. In February, we announced the appointment of Steve Deals, our Chief Financial Officer, effective April 1st. Steve has been with Universal since 2018 and has more than 25 years of experience across finance, corporate development, and business strategy. He is a trusted Universal leader with significant financial expertise, a deep understanding of our operations, and a proven record of strategic execution. With that, I'll now turn the call over to Steve to review our financial results in more detail.

Thank you, Preston. Good morning, everyone. As Preston mentioned, during fiscal year 2026, our flu cured and burly tobacco portfolio performed well, but results were significantly impacted by two areas of our businesses, which I'll discuss during a review of consolidated and segment results. For the fourth quarter, consolidated revenue was $715 million, up 2% from the same quarter of last year. For the full year, consolidated revenue was $2.9 billion, down slightly from the previous exceptional fiscal year. For the quarter, operating loss was $15 million, as compared to an operating income of $43 million for the same quarter of last year. And for the full year, operating income was $169 million, down $64 million, as compared to fiscal year 2025. Lower operating income was mainly driven by two areas. First, the shanks business within our ingredient segment experienced lower profitability and recorded a $41 million non-cash goodwill impairment. And I'll address both of these items in more detail later. Second, higher inventory write downs in our non-wrapper dark air cured tobacco business combined with weaker performance. For the fourth quarter, net loss attributable to Universal was $43 million as compared to net income of $9 million for the same quarter of last year. For the full year, net income was $33 million, down from $95 million for fiscal year 2025. Lower net income was again mainly the result of the non-cash charges I just mentioned as well as weaker performance at Shanks and our dark air-cured tobacco business. In terms of segment results, tobacco segment revenue was $632 million for the fourth quarter of fiscal 2026, up 3% versus the same quarter of last year. For the full year, revenue was $2.6 billion, down slightly as compared to fiscal year 2025. Segment operating income was $27 million for the fourth quarter of fiscal year 2026, as compared to $46 million for the same quarter of last year. For the full year, segment operating income was $212 million, as compared to $240 million for fiscal year 2025. Lower segment operating income was mainly the result of lower profitability and higher inventory write-downs of non-wrapper dark-air cured tobaccos. Specifically, for fiscal year 2026, total inventory write-downs for our tobacco operations segment were $43 million as compared to $19 million during fiscal year 2025 and an average of $14 million across the five years from fiscal year 2021 through 2025. Now turning to the ingredients operating segment, segment revenue was $83 million for the fourth quarter of fiscal year 2026 as compared to $90 million for the same quarter of last year. For the full year, revenue was $348 million, up 3% as compared to fiscal year 2025. Segment operating income was $2 million for the fourth quarter of fiscal year 2026 as compared to $4 million for the same quarter of last year. For the full year segment, operating income was $3 million, as compared to $12 million for fiscal year 2025. Despite significant industry headwinds, our fruit, smart, and silver businesses performed in line with expectations. Lower operating income for the segment was mainly the result of SHANK's performance and driven by higher fixed and operating costs, related to the recent growth investments as we build our new product pipeline. Regarding liquidity and capital structure, as of March 31, 2026, our net debt was $845 million, compared to $817 million at the same point last year. The increase was mainly the result of higher working capital usage associated with purchasing and selling a significantly larger tobacco crop. Our liquidity availability, which includes cash and availability under our committed and uncommitted credit lines, totaled over $1.2 billion. Now I'll briefly shift to an introduction as Universal's new CFO. As Preston mentioned, I joined Universal in 2018, coinciding with the company's rollout of the enhanced capital allocation strategy. Since then, I've been closely involved in developing and executing that strategy, including the formation of Universal Ingredients platform through three acquisitions and the continued investment in its commercial and operational capabilities. At the same time, I have led our financial planning and analysis function supporting the company through a full supply-demand cycle in leaf tobacco, the complexities of COVID, and the evolving macroeconomic environment that followed. Because of these experiences, I have a clear perspective on both the durability of our core business and the importance of financial discipline as we invest in growth. I am greatly honored to take on the role of Chief Financial Officer. Universal combines a resilient market-leading leaf tobacco business with an adjacent ingredients platform that has a strong core product and customer base, expanding capabilities, and a long runway for growth. My priority is to deliver dependable free cash flow and balance sheet strength through disciplined capital allocation. This approach underpins our commitment to durable shareholder value across agricultural and economic cycles. Now, before I hand the call back to Preston, I would like to address the non-cash goodwill impairment related to Shanks. When we acquired Shanks in October of 2021, we recorded approximately $41 million of goodwill. In accordance with US GAAP, this goodwill was assessed periodically and no indications of impairment were identified prior to fiscal year 2026. Since acquiring the business, we have invested in growth, both in the form of capital expenditures to build new production capabilities and in commercial and R&D human capital. During fiscal 2026, market conditions pressured revenues and profitability for both core products and new product development. As a relatively new player in this space, converting customer interest into sustained revenue and margin growth can be a lengthy process. As of March 31, 2026, we were behind in executing our commercial strategy amidst the market headwinds. In response, management, together with a third-party consultant, conducted a valuation analysis and concluded that a non-cash goodwill impairment was appropriate. To improve execution, we have recently implemented a leadership-level organizational realignment at SHAPES. The focus is on strengthening commercial execution, improving facility utilization, and enhancing financial and operational efficiency. Strategically, Shanks remains a key component of our ingredients platform, given its underutilized capacity, technical capabilities, and role in supporting innovation and solution-based offerings. As CFO, I will focus on strengthening the execution and financial discipline across the company, ensuring we convert strategic intent into financial performance, and on growing revenue and margins, controlling costs, and deploying capital effectively to support growth, both organically and through future accretive acquisition opportunities. I'll now turn the conversation back to Preston.

Thank you, Steve. As we look ahead to fiscal year 2027, our leaf tobacco business brings over 100 years of experience operating through complex and evolving global environments. Combined with our broad geographic diversification and longstanding customer relationships, this positions us well to manage ongoing oversupply and current market dynamics. In ingredients, our strategy is centered on clean label, healthy, organic, and solution-based products and remains aligned with our customers' priorities. We will continue to support our customers as we work together to navigate the persistent market headwinds. Our ingredients focus remains on disciplined execution, including leveraging the investments we have made, strengthening commercial effectiveness, achieving operational efficiencies, and improving financial performance. We enter fiscal year 2027 focused on maximizing and optimizing our tobacco business, growing our ingredients business, and strengthening our company for the next 100 years. This strategic approach strengthens the durability of our business and positions us to navigate market cycles and volatility while continuing to deliver long-term value to our shareholders, like our recent announcement of our 56th consecutive annual dividend increase. Thank you again for joining us today. We will now open the call for questions.

Thank you. The floor is now open for questions. If you have dialed in and would like to ask a question, please press star 1 on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star 1 again. If you're listening via loudspeaker on your device, please remember to pick up your handset and remove yourself from mute before asking your question. Your first question comes from the line of Daniel Harriman of Sidoti. Your line is open.

Thank you. Hey, guys, good morning, and Steve, congratulations on the new role. I'll start with two questions today, and then I'll get back into the queue. But, Preston, can you just talk about your confidence level that we'll get inventory normalization during fiscal 2027? I know uncommitted inventories were 27%, I believe, and then I wanted to see if there's any additional write-down risk in non-wrapper dark air-cured tobacco. And then if we set aside the impairment and the tobacco inventory write-downs, it appears that the overall business is operating at a high level. So I was just wondering if you could speak about the underlying trends in flu-cured Burley and the ingredients platform outside of Shanks and kind of what that tells you about the setup for fiscal 27. Thanks.

Thanks, Daniel. I'll start with the inventory. Yeah, so that inventory number we disclosed, that's as of March 31st, 2026. And leading into that, we've had some buying, you know, early days of buying, but buying in Brazil. So, some of that is what we bought in Brazil. But we've already seen movement from March 31st, just over the last two months. You know, we're confident that we will be within our range for uncommitted inventory between 10% and 20% during the fiscal year, and we'll have a much better update and a much better view of things for our first quarter call in a couple months. But at the moment, we're pleased with where things are going, and like I said, we're confident we'll be within that range during the fiscal year. For the dark write-downs, you know, we've taken those write-downs in particular in the fourth quarter through a sort of a thorough review of inventory on hand and market dynamics. All of that goes into sort of the accounting side of how we evaluate and determine write-downs to take. That was a thorough review at the end of the fiscal year based on current market dynamics. And going into this year, we feel comfortable that inventory positions are good, that we're working closely with our customers to make sure we have the volumes and the quality in particular that they need of non-wrapper and of wrapper tobaccos. And we'll monitor it throughout the year. And there's an accounting side to it where we We always assess, no matter what the tobacco style, we assess our inventory positions and values through the accounting rules, and we'll continue to do that during the year. But at the moment, given the extent of the fourth quarter write-downs, we're comfortable where we are right now with current market dynamics.

Yeah, just to follow on from the accounting side of that, we record inventory at the lower of cost or what we estimate as net realizable value. And that's where, as Preston said, we did a deep dive into our inventories in Q4 to come up with the estimates that we did so we feel good about going into this coming year.

Yeah. I think your other question is a little more about view of fiscal year 27. And on both ingredients and, and the tobacco side, in particular, Fletcher and Burleigh. So on the tobacco side, it's, it's very early in the season for us, you know, markets are really just starting. In Brazil, we are buying in Africa and our footprint buying has started recently. The oversupply carries over from the transition this past fiscal year 26. From under supply to balance to oversupply all in one time, based on really large crops feeds into this year where we also see large crops really across the world, flu cure and Burley. Even though it's early days, we have a lot of experience with our strong local teams in managing crops in any type of market cycle, including oversupply. The key for us is our geographic footprint, where we can mitigate risks from one origin to another based on current conditions. Our really sort of broad portfolio of customers that require all the styles, Blue Cure and Burley, and all the origins where we are, and we're in all the strategic origins. And maybe most importantly, A lot of deep experience in knowing how to buy and how to buy the right grades at the right price. And when we look at the undersupply years, there were places in the undersupply years where we were really forced and the market was forced to pay really high prices for practically all grades because it was such an undersupply. In oversupply, we have more flexibility. We have access to the tobacco we need. The larger crops give us also some additional benefits like third-party processing because of larger crops being handled by others. And we could be more, I'd say, more intentional, more strategic, and more efficient in how we buy. So we know we're buying the right grades at the right prices. and then we can move them and try to protect margins with oversupply and with customers who have built up durations over the past few years with their large purchases. It's very important that we're buying correctly, but we're also keeping in close contact with our customers so we know their demands, they know their needs, and we can plan accordingly. And that will continue throughout the year, but so far that's been going well. And we are encouraged where we are despite lots of market dynamics. And it's early. So we'll continue that good work. But on the tobacco side, we feel good. We are experienced and we're entering it with the right strategies. On the ingredient side, also encouraged. You know, we're very happy with the strategy of ingredients. And with shanks as an important part of that, as Steve had mentioned, we see inflationary pressure and some of the other market headwinds persisting into this year. So we will continue to navigate those. And I think for things, for example, like tariffs, I think we did a good job of navigating a lot of the direct impacts of tariffs this past year to minimize the costs that are going into our inventory. and taking advantage of opportunities we had where maybe domestic sourcing gave us opportunities versus others who are sourcing overseas and paying those higher tariffs. With maybe more normalized tariffs this year, and, you know, it'll also be fluid with tariffs, but if tariffs remain lower this year or even go away, I am optimistic that that will reduce some inflationary pressure that our customers feel with their own sales and products, and certainly on the tariff side, impacts on their business from tariffs that are more direct to them. But that will give us opportunities to increase the volumes we would otherwise have sold to those customers as pasture with those headwinds, and with the increased volumes, you know, focus on increased profitability and cost absorption. So I'm happy with where we are happy with our strategy. I'm really excited about what we're doing with universal ingredients and where it can go. And we're putting in the hard work. And we're absolutely committed to growing our ingredients business. In particular, in shanks, executing these initiatives, we're operating as efficiently and as profitably as we can operate this year.

Thanks, guys. I really appreciate it.

Sure. And again, if you have a question, please press star 1 on your telephone keypad to raise your hand and join the queue. We have a follow-up question from the line of Daniel Harriman of Sudoti. Please go ahead.

Hey, guys. I'm back. I guess I'll follow up with one more if there are no other questions. Sorry about that. No, no problem. Steve, kind of like I mentioned, congratulations on the role, and I understand that you're not at all new to Universal and you're not new to financial management or – or really corporate development. But can you just kind of remind us of the company's capital allocation priorities and how you see the balance breaking down in the coming year, maybe between the dividend leverage and then continued investment in ingredients?

Sure. Thank you, Daniel. I really appreciate it. It's great to speak with you today. Yeah, so our capital allocation strategy, which we announced right around the time I joined the company in 2018 – It really has four pillars, strengthening and investing for growth in our leaf tobacco business, increasing our strong dividend, and exploring growth opportunities for our plant-based ingredients business. And then finally, returning excess capital through share repurchases. So that strategy hasn't changed. It's still consistent. As far as the dividend goes, we are a strong cash generating company and our dividend payout ratio on our reported net income this year is over 100%. But if you look back kind of over the last five years on an adjusted net income basis, it's been below 75%. So we feel really good about our positioning and our ability to continue to fund the dividend going forward. You know, that said, our board certainly reviews and management with the board reviews our capital allocation strategy regularly and, you know, could make decisions based on new information that comes along. But as we sit here now, we see no change. And from the ingredients kind of M&A strategy standpoint, no change there. We have not acquired any businesses since Shanks in 2021. We've invested in organic growth. We are now in kind of the phase of realizing the returns on that investment and earning the right for future growth. And so as we kind of pull through this current expansion at Shanks and get new volumes through that facility to really leverage the cost structure that we have in place and the R&D and commercial people that we put in place, that's our focus now. And once we achieve that, we will feedback in and investing in new opportunities for growth.

Daniel, if I can add on to that, in particular, the top of our priorities, which is investing in our tobacco business, you know, we've got such a strong tobacco business. And even this year, you know, if you take away the write-downs, primarily the dark air cured non-wrapper write-downs, the rest of the business performed really well. And our tobacco business is so strong. We see lots of opportunities in terms of market share growth, volume growth, other opportunities for services that we see lots of opportunities to continue to invest in tobacco. At the same time, we're absolutely committed to investing in what we need to grow ingredients as well. So our capital allocation strategy hasn't changed. I don't see it changing. Because I think it's the right strategy for us to grow the company as a whole, but both sides really have good opportunities going forward. I'm really happy with the priorities that we have in continuing to invest in tobacco.

Steve, seeing that you, you know, came to Universal at the beginning of the rollout with ingredients and where you are now, can you, and you talked about this a little bit in the prepared remarks, but Could you just kind of talk us through what that experience has shown you and prepared you and how you think you will use that in the CFO role and then maybe how that, you know, how you incorporate that view into the long-term value proposition of the ingredients platform that some other people like us may not have a view on?

Yes. So, I mean, coming in to the role, As a public company CFO, you know, my number one priority is to maximize long-term shareholder value by driving profitable growth, securing strict regulatory compliance, and optimizing capital allocation. So I think achieving that falls into kind of four main categories, all that are underpinned by human capital management. First is on financial stewardship. So I must continue to build on the strong culture that we have here at Universal around compliance, financial reporting, tax, audit, all the nuts and bolts of finance. Second is kind of taking that to the next level around financial excellence. So this is about continuous improvement. All the areas like budgeting, forecasting, capital structure optimization, tax strategies, cost management, capital decision-making. And in order to do all of this, we just need to make sure, I need to make sure that we have the right people and the right systems and tools in place to achieve that. Third is around supporting Creston and the board on executing the strategy that we've decided upon and maximizing in the four areas that I just talked about, maximizing and optimizing tobacco, growing ingredients, strengthening for the future, and committing to the dividends. And so this includes not only ensuring that the strategy and vision flow through the finance organization, but partnering with the other resource groups and operations around the world to make that happen. And that kind of brings it to the fourth and final category of telling the story around the strategy. So Universal, I believe, is uniquely positioned in the agri-product space as a market-leading leaf tobacco processor. We have over 100 years of proven performance combined with the developing and ingredients business position for long-term growth and value creation. And I'm excited to engage with potential investors and other external shareholders to tell that story.

With no further questions, that concludes our Q&A session. I will now turn the conference back over to Preston Wigner for closing remarks.

Thank you, J.O. Thank you for joining our call today. We look forward to speaking with you during our fiscal year 2027 first quarter call in the coming months.

This concludes today's conference call. You may now disconnect.